



IC H, D 2013 2014. J 2013 2014. E C IC H 60 30 (A, 3D C ) 30 (B, ).

**Results**

43.73 ( D 7.741) 3D C 46.8 ( D 7.513) . I A 17 (57%) B 20 (67%). A 43% III 57% I -A. I 36.7% 76.3% B III (63.3%) 7(40%) I -A. 1. 2 A (<0.05). 1<sup>a</sup>, 2<sup>a</sup>, 4<sup>a</sup> 7<sup>a</sup> . H , 5<sup>a</sup> 6<sup>a</sup> B A. 3 2 1<sup>a</sup> 2 0 A B (<0.05). 2 . A 1<sup>a</sup>, 2<sup>a</sup>, 3<sup>a</sup>, 5<sup>a</sup> 6<sup>a</sup> . B 4<sup>a</sup> 7<sup>a</sup>

B A. 1<sup>a</sup>, 2<sup>a</sup>, 4<sup>a</sup> 7<sup>a</sup> H , 3<sup>a</sup>, 5<sup>a</sup> 6<sup>a</sup> A B (<0.05) ( 3). A 6 , B (F) A. A F 67% A 80% B. A 12 . B F A B. ( =9.77 ( =1); =0.002) 4). I A 12 (40.0%) B 3 (10.0%). (<.05); 11 (36.7%) 14 (46.7%) . 3 A 5 B. F A B 8 B . A B H , ( =0.109) ( 4).

**Discussion**

F 5 . A 8% 6,7 . 100 8 . I A 70

| Week                 | Grade   | Oral mucositis toxicity |      |                      |      | p-value | Hematological toxicity |      |                      |      | p-value |
|----------------------|---------|-------------------------|------|----------------------|------|---------|------------------------|------|----------------------|------|---------|
|                      |         | 3D CRT (Arm A)          |      | Conventional (Arm B) |      |         | 3D CRT (Arm A)         |      | Conventional (Arm B) |      |         |
|                      |         | n                       | %    | n                    | %    |         | n                      | %    | n                    | %    |         |
| 2 <sup>nd</sup> week | Grade 0 | 10                      | 33.3 | 20                   | 66.7 | 0.01    | 20                     | 66.7 | 24                   | 80   | 0.243   |
|                      | Grade 1 | 20                      | 66.7 | 10                   | 33.3 |         | 10                     | 33.3 | 6                    | 20   |         |
| 3 <sup>rd</sup> week | Grade 0 | 0                       | 0    | 14                   | 46.7 | <0.001  | 7                      | 23.3 | 21                   | 70   | 0.001*  |
|                      | Grade 1 | 21                      | 70   | 15                   | 50   |         | 22                     | 73.3 | 8                    | 26.7 |         |
|                      | Grade 2 | 9                       | 30   | 1                    | 3.3  |         | 1                      | 3.3  | 0                    | 0    |         |
| 4 <sup>th</sup> week | Grade 0 | 0                       | 0    | 1                    | 3.3  | 0.024   | 0                      | 0    | 1                    | 3.3  | 0.148*  |
|                      | Grade 1 | 13                      | 43.3 | 22                   | 73.3 |         | 1                      | 3.3  | 7                    | 23.3 |         |
|                      | Grade 2 | 17                      | 56.7 | 7                    | 23.3 |         | 20                     | 66.7 | 16                   | 53.3 |         |
| 5 <sup>th</sup> week | Grade 1 | 2                       | 6.7  | 19                   | 63.3 | <0.001  | 7                      | 23.3 | 6                    | 20   | 0.001   |
|                      | Grade 2 | 24                      | 80   | 10                   | 33.3 |         | 2                      | 6.7  | 1                    | 3.3  |         |
|                      | Grade 3 | 4                       | 13.3 | 1                    | 3.3  |         | 0                      | 0    | 10                   | 33.3 |         |
| 6 <sup>th</sup> week | Grade 1 | 0                       | 0    | 15                   | 50   | <0.001  | 18                     | 60   | 16                   | 53.3 | 0.002   |
|                      | Grade 2 | 15                      | 50   | 9                    | 30   |         | 12                     | 40   | 4                    | 13.3 |         |
|                      | Grade 3 | 15                      | 50   | 6                    | 20   |         | 0                      | 0    | 9                    | 30   |         |
|                      | Grade 4 | -                       | -    | -                    | -    |         | 15                     | 50   | 18                   | 60   |         |
| 7 <sup>th</sup> week | Grade 0 | 0                       | 0    | 2                    | 6.7  | <0.001  | 13                     | 43.3 | 3                    | 10   | 0.002   |
|                      | Grade 1 | 0                       | 0    | 3                    | 10   |         | 1                      | 3.3  | 0                    | 0    |         |
|                      | Grade 2 | 6                       | 20   | 20                   | 66.7 |         | 1                      | 3.3  | 0                    | 0    |         |
|                      | Grade 3 | 24                      | 80   | 5                    | 16.7 |         | 0                      | 0    | 4                    | 13.3 |         |

\* Fisher's Exact Test

**Table 1:** Distribution of the patients by oral mucositis and hematological toxicity.



0. F  
 2. A 2. B (<0.05).  
 1.  
 0  
 0  
 24 6  
 B.  
 (=0.542). B 5  
 A B (<0.05). I , 3  
 G 11.  
 10% 12.

A  
 B 3, 5<sup>B</sup> 6<sup>B</sup> (<.05). I  
 1<sup>B</sup> 2<sup>B</sup> 4<sup>B</sup> 7<sup>B</sup>

6  
 A. A F  
 (F) 67% A  
 80% B. A 12  
 B F  
 B. (=0.002).

I A 12 (40.0%)  
 B 3 (10.0%).  
 (<.05); 11  
 (36.7%) 14 (46.7%)  
 3 A 5 B. F  
 A 8 B  
 A B H ,  
 (=0.109).  
 C 3D C  
 (<.05).

### Conclusion

I ,  
 D 70 G C (3DC ) 2D  
 66 G

### References

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Kulkarni MR (2013) Head and Neck cancer burden in India. International journal of head and Neck surgery 4: 29-35.
3. Hospital cancer registry report published
4. Practical Radiotherapy Planning
5. Traynor AM, Richards GM, Hartig GK, Khuntia D, Cleary JF, et al. (2010) Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience. Head Neck 32: 599-606.

IC H 2008-2010 3.  
 C 7 A III  
 (23.3%) B III 63.3%.  
 23 A I A  
 B 11.  
 (=0.002) ... III  
 I A 3D  
 C  
 A 1<sup>B</sup>  
 0 F 2 7<sup>B</sup>  
 A  
 B (<.05).  
 9.  
 1<sup>B</sup>  
 0  
 1  
 2 A 0  
 B.  
 (=0.355).  
 A 2  
 (=0.243). H , 3  
 A B  
 5<sup>B</sup> 6<sup>B</sup> 4<sup>B</sup> 7<sup>B</sup>  
 K 10.  
 A 1<sup>B</sup> 2

6. Haddad RI, Shin DM (2008) Recent advances in head and neck cancer. *N Engl J Med* 359: 1143-1154.
7. Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. *Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet* 355: 949-955.
8. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, et al. (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. *N Engl J Med* 349: 2091-2098.
9. Jamshed A, Hussain R, Jamshde S, Syed AA, Loya A, et al. (2010) Concomitant chemoradiation in locally advanced laryngeal cancer. *IJHNS* 1: 153-160.
10. Kose F, Besen A, Sumbul T, Sezer A, Karadeniz C, et al. (2011) Weekly cisplatin versus standard three-weekly cisplatin in concurrent chemoradiotherapy of head and neck cancer: the Baskent university experience. *Asian Pacific Journal of Cancer Prevention* 12: 1185-1188.
11. Belderbos J, Heemsbergen W, Hoogeman M, Pongel K, Rossi M, et al. (2005) Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. *Radiother Oncol* 75: 157-164.
12. Meijer GJ, Bruinvis IA, Mijnheer BJ, Lebesque JV (2000) A treatment planning method to correct dose distributions distorted by setup verification fields. *Int J Radiat Oncol Biol Phys* 46: 1319-1328.

**Citation:** Shafatujjahan, Chowdhury Q, Islam J, Chowdhury MMR, Begum FA, et al. (2016) Comparison of 70 Gy 3DCRT with Concurrent Chemotherapy versus Conventional 66 Gy Radiotherapy with Concurrent Chemotherapy in Locally Advanced Squamous Cell Carcinoma of Larynx. *Adv Cancer Prev* 1: 105. doi:[10.4172/2472-0429.1000105](https://doi.org/10.4172/2472-0429.1000105)